SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.

Sacha I. Rothschild,Alfred Zippelius,Spasenija Savic,Michel Gonzalez,Walter Weder,Alexandros Xyrafas,C. Rusterholz,Miklos Pless

SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.

2016

Sacha I. Rothschild
Alfred Zippelius
Spasenija Savic
Michel Gonzalez
Walter Weder
Alexandros Xyrafas
C. Rusterholz
Miklos Pless

TPS8573Background: Improving the outcome of locally advanced non-small cell lung cancer (NSCLC) is one of the major challenges in thoracic oncology. SAKK substantially contributed to establish a st...

Keywords:

non-small cell lung cancer (NSCLC)
Antibody
Pathology
PD-L1
Oncology
Stage IIIa
Durvalumab
Medicine
Internal medicine
Chemotherapy
Thoracic Oncology
in patient
anti pd 1

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations